G M1 -and G M2 -gangliosidoses are lethal lysosomal diseases that are caused by a defect of acid hydrolases, resulting in the intralysosomal accumulation of the specific physiological substrates, G M1 -and G M2
G M1 -and G M2 -gangliosidoses are lethal lysosomal diseases caused by a disorder of catabolism by lysosomal enzymes ␤-galactosidase and ␤-hexosaminidase A, respectively. 1, 5 These diseases are manifest as progressive motor dysfunction, which results from the intralysosomal accumulation of specific physiological substrates, G M1 -and G M2 -gangliosides, respectively, and the subsequent destruction of neurons. In domestic animals, naturally occurring gangliosidoses have been reported in dogs, cats, calves, and sheep in G M1 -gangliosidosis and in dogs, cats, pigs, and deer in G M2 -gangliosidosis. 4, 6, 8, 11 In veterinary clinics, many lysosomal diseases including gangliosidoses in animals are not investigated to a definitive diagnosis both because their devastating neurologic features make them difficult candidates for such an investigation and because there are few centers capable of providing practical diagnostic assistance. 4 Generally, it is needed both to identify the storage materials in the central nervous system and to demonstrate the defect of a specific enzyme for the definitive diagnosis of lysosomal diseases. Therefore, these diseases are diagnosed by postmortem examination in most cases. An early diagnosis using samples obtained with minimal invasiveness from living animals results in a quick determination of the prognosis of the affected animals.
The objective of the present study is to establish a method of measuring the concentration of G M1 -ganglioside in canine cerebrospinal fluid (CSF) and discuss the usefulness of this method for the diagnosis of canine G M1 -gangliosidosis.
Canine CSF was obtained from 5 clinically healthy dogs (2-9 years old) and 4 Shiba dogs with G M1 -gangliosidosis (5-12 months old), which belonged to a breeding colony of canine G M1 -gangliosidosis maintained in the Graduate School of Veterinary Medicine, Hokkaido University in Sapporo, Hokkaido, Japan. The affected dogs were diagnosed based on clinical signs 8 and the results of an enzyme assay 10 and a DNA mutation assay. 7 In addition, CSF from a 15month-old golden retriever with the G M2 -gangliosidosis 0 variant (Sandhoff disease) 9 was also used in the present study. Canine CSF collected from dogs under anesthesia was frozen at Ϫ80 C until use.
Canine CSF gangliosides were extracted according to the method reported previously. 2, 11 The concentration of G M1ganglioside in CSF was determined using thin-layer chromatography (TLC)-enzyme immunostaining as described previously, 2,11 with some alterations for the analysis of G M1ganglioside. A sample of the ganglioside extract dissolved in chloroform-methanol (2:1, vol/vol), which corresponded to 50 or 100 l of CSF, was applied to a TLC plate, a and then the plate was developed with chloroform-methanol-12 mM MgCl 2 -15 M NH 4 OH (60:40:7.5:3, vol/vol/vol/vol). After the plate had been dried by blowing warm air on it, it was again developed with chloroform-methanol-12 mM MgCl 2 (58:40:9, vol/vol/vol) in the same direction and then dried. The plate was soaked in solution A (10 mM phosphate-buffered saline [PBS], pH 7.4, containing 1% egg albumin b and 1% polyvinylpyrrolidone [K-30, MW 40,000] b ) at room temperature for 30 minutes after it was developed with solution A diluted 10-fold with PBS in the same direction as the first 2 times. The plate was treated with biotinconjugated cholera toxin B c or biotin-conjugated mouse anti-G M1 -ganglioside antibody d in solution A (1:500 dilution ratio) at 37 C overnight. After the first reaction the plate was washed with 10 mM PBS containing 0.1% Tween 20 e and soaked in solution A at 37 C for 15 minutes. The plate was then treated with horseradish peroxidase-conjugated streptavidin f in 10 mM PBS containing 3% polyvinylpyrrolidone (1:1,000 dilution ratio) at 37 C for 2 hours and washed with 10 mM PBS. The band of G M1 -ganglioside was observed by a peroxidase reaction involving 4-chloro-1-naphthol b as a chromogenic substrate. Purified G M1 -ganglioside, g which was quantitatively determined by a method reported previously, 3 was used as a standard for densitometric scanning. h Figure 1 shows the result of the TLC-enzyme immunostaining using biotin-conjugated cholera toxin B in the first reaction. G M1 -ganglioside in CSF was detected clearly as a band with a mobility similar to that of G M1 -ganglioside standard in both a normal dog and a dog with G M1 -gangliosidosis. The band in the dog with G M1 -gangliosidosis was much denser than that in the normal dog. Furthermore, the band of G M1 -ganglioside in the dog with Sandhoff disease was also denser than that in a normal dog, but its density was lower than that of a dog with G M1 -gangliosidosis (Fig.  2) . On the other hand, G M1 -ganglioside in canine CSF could not be observed by the method using mouse anti-G M1 -ganglioside antibody in the first reaction (data not shown). Table 1 shows the concentration of CSF G M1 -ganglioside in normal dogs and dogs with G M1 -gangliosidosis or Sandhoff disease, analyzed by a densitometric method. The concentration of CSF G M1 -ganglioside in dogs with G M1 -gangliosidosis was markedly higher than the mean value in normal dogs. The increased level in dogs with G M1 -gangliosidosis was approximately proportional to their age: 9-fold at 5 months, 14-fold at 9 months, 29-fold at 10 months, and 51fold at 12 months of age compared with the mean value in normal dogs. In addition, the concentration of CSF G M1 -gan-glioside in the dog with Sandhoff disease was 7 times the normal level.
In the present study it was demonstrated that the concentration of CSF G M1 -ganglioside was increased in dogs with G M1 -gangliosidosis, and the increased level was approximately proportional to the age of the dogs. The concentration was high in the affected dog even at 5 months of age, when Shiba dogs with G M1 -gangliosidosis first manifest neurologic signs. 8 From these results, it is concluded that this analytical method for the measurement of CSF G M1 -ganglioside is useful for the diagnosis of canine G M1 -gangliosidosis. It was previously reported that the amount of G M1 -ganglioside was more than 20 times the normal level in the cerebral cortex and more than 10 times the normal level in the cerebral medulla in a 10-month-old Shiba dog with G M1 -gangliosidosis. 10 Therefore, the increase of CSF G M1 -ganglioside is thought to be due to an accumulation of G M1 -ganglioside in the central nervous system and leakage from the tissue to CSF.
The 15-month-old golden retriever was reported as the first case of Sandhoff disease in canine G M2 -gangliosidosis. 9 The disease was diagnosed based on deficient activities of ␤-hexosaminidase A and B in leukocytes and an accumulation of G M2 -ganglioside in CSF to 46 times the normal level. 9, 11 In addition, leukocyte ␤-galactosidase activity in the dog was within normal limits. 9 In the present study, however, a moderate accumulation of G M1 -ganglioside was observed in the CSF, although the dog has a normal ␤-galactosidase that hydrolyzes G M1 -ganglioside to G M2 -ganglioside and galactose. The accumulation of CSF G M1 -ganglioside may be due to the destruction of neuronal cells due to excessive intralysosomal accumulation of G M2 -ganglioside and the subsequent leakage of various gangliosides into CSF. This suggests a need to not only analyze CSF gangliosides but also measure specific enzyme activity for a definitive diagnosis of gangliosidoses.
In conclusion, the laboratory technique developed in the present study enables a definitive and early diagnosis of ca-nine G M1 -gangliosidosis even if tissues and organs cannot be obtained. However, because G M1 -ganglioside can also be elevated in cases of G M2 -gangliosidosis, it is necessary to assay for specific enzyme deficiencies to definitively separate G M1from G M2 -gangliosidosis.
